The outbreak of COVID-19 has not only posed significant challenges to public health but has also shed light on the connection between the virus and inflammatory diseases. COVID-19, caused by the SARS-CoV-2 virus, has been associated with various inflammatory conditions, such as pneumonia and acute respiratory distress syndrome (ARDS). Understanding and addressing the inflammatory response triggered by the virus is crucial in developing effective treatments. In this context, Dr. Nashat Abu Salah, Director of the Corona Department and Director of the Geriatrics Department at Ziv Medical Center in Safed, shares insights on the success of the clinical trial for a potential cure for corona patients.

The trial utilized the new drug AMOR18, developed in Israel in collaboration with the inflammation global care, which showed promising results in treating COVID-19 patients. Administered through inhalation and as a powder under the tongue, this unique medication containing amorphous calcium carbonate as the active substance has demonstrated a remarkable 100% success rate, leading to swift recovery and subsequent discharge of patients. These encouraging outcomes bring hope not only to the corona patients in Israel but also to the broader field of medicine worldwide.